Q4 2025

Imunon's Transformative Year: Groundbreaking IMNN-001 Results Set New Standard for Ovarian Cancer Treatment

IMNN

Imunon's Transformative Year: Groundbreaking IMNN-001 Results Set New Standard for Ovarian Cancer Treatment

Imunon, a pioneering biotechnology company, made history with its fourth quarter and full year 2025 financial results, showcasing a truly transformational year in the fight against ovarian cancer. The company's proprietary IL-12 immunotherapy, IMNN-001, has demonstrated unprecedented potential to redefine frontline treatment for women with newly diagnosed advanced

By Mason Lankes
Innventure Sees Decisive Inflection in Trajectory as Commercial Bookings Soar and Platform Transitions to Self-Funding

INV

Innventure Sees Decisive Inflection in Trajectory as Commercial Bookings Soar and Platform Transitions to Self-Funding

Innventure, a leader in industrial growth platforms, has announced a significant milestone in its fourth quarter 2025 earnings call. Chief Growth Officer Roland Austrup declared that the company has crossed the threshold from potential to performance, with third-party validation, commercial bookings at scale, operational expansion, and execution milestones delivered across

By Evan Tressler